Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
October 4th, 2017
6.8K views
We describe a method to quantify the aggregation of misfolded proteins. Our protocol details lentiviral induced stable cell line generation, automated confocal imaging, and image analysis of protein aggregates. As an illustrative application, we studied the effect of small molecules in promoting SOD1 aggregation in a time- and dose-dependent manner.
Overview
This study describes a method for quantifying the aggregation of misfolded proteins, particularly focusing on investigating the effects of small molecules on SOD1 aggregation. The approach incorporates lentiviral-induced stable cell line generation, automated confocal imaging, and detailed image analysis. This method aims to facilitate high-content screening relevant to neurodegenerative disorders.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Neurodegeneration
Background
- Protein aggregation is linked to neurodegenerative diseases, such as ALS.
- Understanding the modulation of misfolded proteins can inform therapeutic strategies.
- Cellular assays are essential for high-content screening of potential drug candidates.
Purpose of Study
- To develop an assay for studying the effects of small molecules on protein aggregation.
- To establish a method that supports high-content screening techniques.
- To offer a straightforward approach for quantifying protein aggregation in various conditions.
Methods Used
- The study utilized cell culture models with lentiviral vectors for stable expression.
- HEK-293 T-cells served as the biological model to explore SOD1 protein aggregation.
- Efforts included multiple viral transductions and long-term cell monitoring.
- Automated confocal imaging facilitated the quantification of protein aggregates over time.
Main Results
- The method successful quantified the effects of small molecules on SOD1 aggregation.
- Timelines for aggregation detection and the efficacy of different compounds were assessed.
- Results indicated a time- and dose-dependent relationship in modulation of protein aggregation.
Conclusions
- This study demonstrates a novel method for evaluating the aggregation of misfolded proteins.
- The findings have implications for therapeutic strategies in neurodegenerative diseases.
- Overall, the approach paves the way for further investigations into small molecule effects on protein misfolding.
Frequently Asked Questions
What are the advantages of the described method?
This method provides a simplified way to detect and quantify protein aggregation relevant to neurodegenerative disorders, facilitating high-content screening.
How is the cell model implemented in this study?
HEK-293 T-cells are used as a model for expressing SOD1, allowing for the study of protein aggregation and response to various small molecules.
What types of data are obtained using this method?
The method yields quantitative data on protein aggregation and the effects of small molecules over time, providing insights into aggregation kinetics.
Can this method be adapted for other protein types?
Yes, while focused on SOD1, the method can potentially be adapted for other misfolded proteins associated with different neurodegenerative diseases.
What are the key limitations of this assay?
Limitations include the reliance on cellular models which may not fully replicate in vivo conditions, and the need for rigorous controls in screening assays.
Executive Industry Relevance
This assay enables quantitative, time- and dose-dependent measurement of mutant SOD1 aggregation in living cells, supporting target validation in ALS drug discovery. By linking proteasome inhibition to aggregate formation in a controlled cellular model, it provides mechanistic insight for de-risking SOD1-targeted hypotheses. The approach supports early-stage go/no-go decisions by enabling screening for small molecule modulators of protein misfolding.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates the role of SOD1 A4V mutation in aggregate formation under proteasome stress.
- Operational Value: Uses stable lentiviral expression in HEK-293 cells to ensure consistent mutant protein levels.
- Predictive Value: Enables dose-response analysis of proteasome inhibitors to quantify aggregation kinetics.
Screening & Assay Development
- Scientific Value: Measures aggregate formation via high-content imaging of YFP-tagged SOD1 in live cells.
- Operational Value: Compatible with 384-well plating and liquid handling for compound screening.
- Assay Readiness: Requires signal-to-noise ratio ≥3 for YFP expression to ensure detection fidelity.
Translational & Preclinical Research
- Translational Value: Models SOD1 aggregation observed in familial ALS patient inclusions.
- Mechanistic De-risking: Shows mutant-specific aggregation in HEK-293 but not U2OS or SH-SY5Y, supporting cell line selection.
- Continuity: Enables longitudinal tracking of aggregate formation over 50 hours post-treatment.
Pipeline & Workflow Integration
The assay fits within early discovery workflows, moving from target validation to lead identification by enabling compound screening against SOD1 aggregation.
- Discovery Biology: Tests the hypothesis that SOD1 A4V misfolding drives aggregation in a proteasome-dependent manner.
- Screening: Supports high-content screening of small molecules using automated imaging and 384-well formats.
- Analytics: Generates quantitative readouts of aggregate-positive cells and cytotoxicity via Hoechst staining.
- Translational Research: Models disease-relevant SOD1 aggregation in a living cell system.
- Enterprise Reuse: Establishes a reusable platform for testing aggregation modulators across neurodegenerative targets.
Operational & Enterprise Impact
- Scientific Value: Provides mechanistic insight into SOD1 aggregation and mutant-specific toxicity.
- Operational Value: Standardizes aggregate quantification via fluorescence imaging and image analysis algorithms.
- Strategic Value: Informs go/no-go decisions by identifying compounds that reduce SOD1 A4V aggregation.
- Portfolio Impact: Enables risk-adjusted prioritization of SOD1-targeted candidates based on aggregation modulation.
Implementation Considerations
- Requires expertise in lentiviral transduction and stable cell line generation.
- Depends on fluorescence microscopy and automated image analysis infrastructure.
- Needs standardization across cell lines (HEK-293, U2OS, SH-SY5Y) to control for aggregation variability.
- Requires optimization of proteasome inhibitor dosing and exposure timing.
- Limited to models where mutant SOD1 aggregates upon proteasome inhibition, as seen in HEK-293 but not other lines.
Biopharma FAQs
Why does proteasome inhibitor treatment matter for SOD1 aggregation assays?
Proteasome inhibition induces SOD1 A4V aggregation in HEK-293 cells, enabling quantification of mutant-specific aggregate formation. This approach models cellular stress conditions linked to ALS pathology. It allows dose-response analysis to assess compound effects on aggregation kinetics.
How does isolating the SOD1 A4V variable support target validation in ALS?
Expressing only SOD1 A4V YFP in HEK-293 cells enables direct assessment of mutant-driven aggregation without wild-type confounding. The assay shows aggregation occurs selectively in mutant-expressing cells under proteasome stress. This isolation strengthens the hypothesis that SOD1 misfolding drives pathology.
What quantitative measurements enable compound screening in this assay?
The method quantifies the percentage of cells expressing SOD1 A4V aggregates via high-content imaging. It simultaneously measures cytotoxicity through Hoechst-stained adherent cell counts. These dual readouts allow assessment of compound efficacy and safety in a single workflow.
Why are replication requirements important for cross-functional collaboration in this assay?
Replication across experiments confirms that SOD1 A4V aggregation is consistent in HEK-293 but absent in U2OS and SH-SY5Y lines. This consistency supports reliable data sharing between biology and screening teams. Standardized replication ensures assay robustness for hit confirmation campaigns.
What statistical analysis capabilities are required before implementing this assay for screening?
The assay requires dose-response curve fitting to determine EC50 values of proteasome inhibitors on aggregation. It needs statistical comparison of aggregate-positive cell percentages between treatment and control groups. Analysis of variance or t-tests are used to assess significance of compound effects across replicates.
Chapters in this video
0:05
Title
0:58
Lentivirus Production
2:50
Lentiviral Transduction and Stable Line Generation
4:53
Dose Response Effect of Proteosome Inhibitors on Protein Aggregation and Image Analysis
7:06
Time lapse Imaging of YFP Expression in Living Cells
8:09
Results: Quantification of SOD1 Mutant Protein Aggregate Formation
10:04
Conclusion
